Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics Holdings Limited has launched the retail component of its pro rata accelerated non-renounceable entitlement offer, with documents issued to eligible shareholders and a closing date set for October 2, 2024. The company specializes in point-of-care diagnostic test technology and advises shareholders to review the offer booklet before participating. The offer aims to enable more accurate diagnosis and management of medical conditions through Lumos’ innovative diagnostic tests and reader platforms.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
